BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 132 filers reported holding BRIDGEBIO PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $3,183,360 | -7.6% | 91,020 | +23.8% | 0.47% | +129.3% |
| Q3 2021 | $3,446,000 | -21.9% | 73,500 | +1.5% | 0.20% | -41.1% |
| Q2 2021 | $4,413,000 | -7.4% | 72,400 | -6.5% | 0.35% | -15.9% |
| Q1 2021 | $4,767,000 | -5.3% | 77,400 | +9.3% | 0.41% | +5.1% |
| Q4 2020 | $5,035,000 | +114.7% | 70,800 | +13.3% | 0.39% | +105.2% |
| Q3 2020 | $2,345,000 | -31.4% | 62,500 | -40.4% | 0.19% | -56.6% |
| Q2 2020 | $3,417,000 | +7.6% | 104,800 | -4.3% | 0.44% | -27.4% |
| Q1 2020 | $3,176,000 | +220.5% | 109,500 | +286.9% | 0.61% | +218.8% |
| Q4 2019 | $991,000 | – | 28,300 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |